Abstract
It has been predicted that one of the greatest increase in prevalence of diabetes will happen in the Middle East bear in the next decades. The aim of standard therapeutic strategies for diabetes is better control of complications. In contrast, some new strategies like cell and gene therapy have aimed to cure the disease. In recent years, significant progress has occurred in beta-cell replacement therapies with a progressive improvement of short-term and long term outcomes. In year 2005, considering the impact of the disease in Iran and the promising results of the Edmonton protocol, the funding for establishing a current Good Manufacturing Practice (cGMP) islet processing facility by Endocrinology and Metabolism Research Center was approved by Tehran University of Medical Sciences. Several islet isolations were performed following establishment of cGMP facility and recruitment of all required equipments for process validation and experimental purpose. Finally the first successful clinical islet isolation and transplantation was performed in September 2010. In spite of a high cost of the procedure it is considered beneficial and may prevent long term complications and the costs associated with secondary cares. In this article we will briefly describe our experience in setting up a cGMP islet processing facility which can provide valuable information for regional countries interested to establish similar facilities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akrami SM, Osati Z, Zahedi F, Raza M (2004) Brain death: recent ethical and religious considerations in Iran. Transpl Proc 36:2883–2887
Burger SR (2003) Current regulatory issue in cell and tissue therapy. Cytptherapy 5(4):289–298
Esteghamati A, Gouya MM, Abbasi M et al (2008) Prevalence of diabetes and impaired fasting glucose in the adult population of Iran. Diabetes Care 31(1):96–98
Giordano R, Lazzari L, Rebulla P (2004) Clinical grade cell manipulation. Vox Sang 87:65–72
Hengster P, Hermann M, Pirkebner D et al (2005) Islet isolation and GMP, ISO 9001:2000: what do we need—a 3-year experience. Transpl Proc 37:3407–3408
Hirshberg B, Rother KI, Harlan DM (2003) Islet transplantation: where do we stand now? Diabetes Metab Res Rev 19:175–178
Ichii H, Ricordi C (2009) Current status of islet cell transplantation. J Hepatobiliary Pancreat Surg 16:101–112
Ikemoto T, Matsumoto S, Itoh T et al (2010) Assessment of islet quality following international ship** of more than 10,000 Km. Cell Transplant 19(6):731–741
Langer RM (2010) Islet transplantation: lessons learned since the edmonton breakthrough. Transpl Proc 42:1421–1424
Larijani B, Maleckzadeh H, Pajoohi M et al (2003) Prevalence of diabetes mellitus & impaired glucose tolerance of population aged over 25 in Qazvin. J Qazvin Univ Med Sci 26:41–45
Larijani B, Zahedi F, Taheri E (2004) Ethical and legal aspects of organ transplantation in Iran. Transpl Proc 36:1241–1244
Mahdavi-Mazdeh M, Heidary Rouchi A, Rajolani H et al (2008) Transplantation registry in Iran. Transpl Proc 40:126–128
Noguchi H, Matsumoto S (2008) Islet transplantation at the Diabetes Research Institute Japan. J Hepatobiliary Pancreat Surg 15:278–283
Rezagholizadeh A, Heshmat R, Larijani B (2007) Iranian diabetes guidelines: methods and objectives. Iran J Diabetes Lipid Disord 7(1):115–120
Shapiro J (2002) Eighty years after insulin: parallels with modern islet transplantation. JAMC 167(12):1398–1400
Shapiro AMJ, Ricordi C, Hering BJ et al (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355:1318–1330
Sotta ED, Madalozzo TM, Percegona L et al (2004) Establishing an islet transplantation program in a develo** country. Transpl Proc 36:1700–1703
Acknowledgments
The authors would like to thank, Dr. Eghbal Taheri, Dr. Hossein Adibi, Dr. Mohamad Reza Amini, Bahman Dellalat, Mozhgan Hassanpour, Fereshteh Mohamadi- Jahani and Firozeh Ghaderi for their kindly collaboration. Also we acknowledge Dr. Amir Hossein Tavakoli, Dr. Abbas Khodadadi, Dr.Sanaz Dehghani, Niloufar Tirgar, Dr. Hassan Bahrami-nasab, and the other staff of organ procurement units of Iranian Tissue Bank and Sina Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Larijani, B., Arjmand, B., Amoli, M.M. et al. Establishing a cGMP pancreatic islet processing facility: the first experience in Iran. Cell Tissue Bank 13, 569–575 (2012). https://doi.org/10.1007/s10561-011-9273-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-011-9273-1